Press release
RNA Interference (RNAi) Drug Delivery Market Size Worth US$ 235.1 Billion by 2032 | CAGR 21.4%
Report Highlights:
How big is the RNA interference (RNAi) drug delivery market?
The global RNA interference (RNAi) drug delivery market size reached US$ 69.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 235.1 Billion by 2032, exhibiting a growth rate (CAGR) of 21.4% during 2024-2032.
Request for a Sample Copy of This Report: https://www.imarcgroup.com/rna-interference-drug-delivery-market/requestsample
Factors Affecting the Growth of the RNA Interference (RNAi) Drug Delivery Industry:
Advancements in Delivery Technologies:
Advancements in delivery technologies within the RNA Interference (RNAi) drug delivery market are pivotal for enhancing the therapeutic potential of RNAi-based treatments. These innovations focus on overcoming the primary challenge of efficiently and safely delivering RNAi molecules, such as small interfering RNA (siRNA) and microRNA (miRNA), into target cells. Lipid nanoparticles (LNPs) have emerged as a leading delivery mechanism, offering improved stability and reduced toxicity, facilitating the targeted delivery of RNAi molecules to specific tissues. Additionally, conjugate delivery systems, which attach RNAi molecules to ligands or antibodies, have been developed to enhance cell-specific targeting and uptake. These technological advancements significantly improve the delivery efficiency, specificity, and overall efficacy of RNAi therapies, broadening their applicability in treating a wide array of diseases, including genetic disorders and cancers.
Increasing Prevalence of Chronic and Genetic Diseases:
The increasing prevalence of chronic and genetic diseases globally is a significant driver for the RNA Interference (RNAi) drug delivery market. Chronic conditions such as cancer, hepatitis, and cardiovascular diseases, along with genetic disorders like Huntington's disease and certain forms of blindness, present substantial healthcare challenges. RNAi therapies offer a novel approach by targeting and silencing specific genes responsible for these diseases, providing a mechanism for precise and effective treatment. As the incidence of these conditions rises, so does the demand for innovative treatments that can potentially offer improved outcomes and quality of life for patients. This growing demand propels research, development, and investment in RNAi technology, aiming to expand the arsenal of treatments available against complex diseases, thereby driving market growth.
Supportive Regulatory Environment:
The supportive regulatory environment for the RNA Interference (RNAi) drug delivery market is a crucial driver of its growth, characterized by regulatory bodies facilitating the approval and commercialization of RNAi-based therapies. Agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have recognized the potential of RNAi therapeutics in treating various diseases, including rare genetic disorders and cancers. This recognition has led to an expedited review process for such treatments, reducing the time and resources required for RNAi drugs to reach the market. The regulatory support boosts industry confidence, encouraging increased investment in RNAi research and development. It also ensures that patients gain faster access to innovative treatments, thereby enhancing the overall market growth for RNAi drug delivery systems.
RNA Interference (RNAi) Drug Delivery Market Report Segmentation:
Breakup by Application:
Infectious Disease
Cardiology
Oncology
Neurology
Ophthalmology
Urology
Metabolic Disorders
Others
Oncology represents the largest segment in the RNAi drug delivery market due to the pressing need for innovative and effective treatments for various types of cancer, driving significant research and investment in RNAi-based therapies targeting cancer cells.
Breakup by Technology:
Nanoparticle Drug Delivery
Pulmonary Drug Delivery
Nucleic Acid Drug Delivery
Aptamer Drug Delivery
Nanoparticle drug delivery technology holds the largest share in the RNAi drug delivery market because of its ability to efficiently deliver RNAi therapeutics to target cells, enhancing drug stability, bioavailability, and therapeutic efficacy while minimizing off-target effects.
Breakup by Regional Insights:
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
North America (United States, Canada)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru, Others)
Middle East and Africa ( Turkey, Saudi Arabia, Iran, United Arab Emirates, Others)
North America leads the global RNAi drug delivery market due to factors such as a robust pharmaceutical industry, strong research and development infrastructure, supportive regulatory environment, and high prevalence of chronic diseases like cancer, driving the demand for innovative RNAi-based therapies.
Global RNA Interference (RNAi) Drug Delivery Market Trends:
The significant investment in research and development (R&D) activities aimed at enhancing the specificity and efficiency of RNAi therapeutics represents one of the key factors influencing the growth of the market across the globe. This includes developing novel delivery vectors, such as lipid nanoparticles and conjugate systems, which facilitate the targeted delivery of RNAi molecules to specific cells or tissues, thereby improving treatment outcomes and reducing side effects.
The market is also driven by the growing focus on treating a wider range of diseases, including genetic disorders, cancers, and infectious diseases, leveraging the potential of RNAi mechanisms to silence disease-causing genes. Additionally, there's an increasing collaboration between biotechnology companies and academic institutions to accelerate the development and commercialization of RNAi therapies.
Leading Companies Operating in the Global RNA Interference (RNAi) Drug Delivery Industry:
Alnylam Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
Silence Therapeutics Plc and Sirnaomics Inc.
Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=2758&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release RNA Interference (RNAi) Drug Delivery Market Size Worth US$ 235.1 Billion by 2032 | CAGR 21.4% here
News-ID: 3387008 • Views: …
More Releases from IMARC Group
Automotive Control Cables Manufacturing Plant Setup Report 2025: Machinery, Raw …
Automotive control cables are essential components used to transmit mechanical force in vehicles, enabling the smooth operation of various systems such as brakes, clutches, accelerators, gear shifts, and seating mechanisms. These cables are designed for durability, flexibility, and high performance under diverse driving conditions. Their demand is directly linked to the growth of the automotive industry, aftermarket sales, and increasing consumer preference for enhanced driving comfort and safety.
Setting up an…
Halal Cosmetics Market Size, Trends, Key Players, Opportunity and Forecast 2025- …
IMARC Group, a leading market research company, has recently released a report titled "Halal Cosmetics Market Size, Share, Trends and Forecast by Type, Distribution Channel, and Region, 2025-2033." The study provides a detailed analysis of the industry, including the global halal cosmetics market size, trends, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Halal Cosmetics Market Highlights:
• Halal Cosmetics Market…
Comprehensive Castor Oil Processing Plant Project Report 2025: Setup Guide, Econ …
Castor oil is a versatile vegetable oil extracted from the seeds of the Ricinus communis plant. It is widely used in pharmaceuticals, cosmetics, food processing, lubricants, paints, coatings, and biodiesel production owing to its unique chemical properties, including high ricinoleic acid content. Castor oil derivatives also serve as key raw materials in the polymer, chemical, and industrial sectors.
Establishing a castor oil processing plant involves steps such as seed cleaning, dehulling,…
Honey Processing Plant Report 2025: Capital Investment, Operating Expenses and M …
Honey is a natural sweetener produced by honeybees and is valued for its nutritional, medicinal, and industrial applications. It contains antioxidants, enzymes, vitamins, and minerals that make it a popular ingredient in food and beverages, pharmaceuticals, cosmetics, and personal care products. Processed honey is widely consumed as a sweetener, used in bakery and confectionery items, beverages, dietary supplements, and skincare formulations.
Setting up a honey processing plant involves operations such as…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
